top of page
  • Active, not recruiting

NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Myeloma

Updated: Feb 4

  • NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients


Teclistamab Expanded Access

NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients


The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.

 

Sponsor

 

ClinicalTrials.gov Identifier: NCT05463939

Official Title: Teclistamab US Expanded Access Treatment Protocol for Patients With Relapsed or Refractory Multiple Myeloma

First Posted : July 19, 2022

Click here to see details on ClinicalTrials.gov

 
 

Drug: Teclistamab

 

Locations

United States

Europe

France

Germany

Italy

 

RELATED POSTS


TECLISTAMAB STUDIES:


NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)


NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)


NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)


NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)


NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma


NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

 

TALQUETAMAB STUDIES:


NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1


NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma


NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma


NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma

 

TECLISTAMAB AND TALQUETAMAB STUDIES:


NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma


NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2






Comments


Commenting has been turned off.
Posts Archive
bottom of page